Affimed appoints Chief Business Officer
Affimed Therapeutics AG announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer.
Dr. Lang joins Affimed from Scil Technology where he was Vice President of Corporate Development. At Scil Technology, he was responsible for the commercial development of a portfolio of regenerative medicine products including an eye-catching deal with Pfizer earlier this year. In his 16 years experience in the biotechnology sector, spanning basic research, industrial R&D, Business Development & Licensing, and commercial operations & management, Dr. Lang contributed significantly in the scientific development and commercialization of biological agents for industrial and healthcare applications.
Dr. Lang replaces Gavin D Clark who has been working as VP Business Development for the last 2 years. Mr Clark is a founding partner at Procela Partners Limited and he will be continuing to consult for a number of early stage Biotech and Discovery Science based companies both in EU and US.
Dr. Lang combines a background as scientist and project manager with extensive experience in the commercialisation of biotechnology products. He has also gained considerable CMC/Production experience in his previous positions. Dr. Lang received his Ph.D. from the Technical University of Brunswick. After that he worked as an industry scientist and project manager with UCB-Celltech and Fresenius-Kabi, respectively. He joined Cosmix GmbH, Brunswick as Head of Business Development, and later Chief Operating Officer. Following Cosmix and prior to joining Scil Technology he was Vice President of Business Development at Pieris Proteolab AG.
Other news from the department people
